Last reviewed · How we verify

Moxifloxacin (M)

Global Alliance for TB Drug Development · FDA-approved active Small molecule

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired bacterial pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.

At a glance

Generic nameMoxifloxacin (M)
SponsorGlobal Alliance for TB Drug Development
Drug classFluoroquinolone antibiotic
TargetDNA gyrase; Topoisomerase IV
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Moxifloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria. It is particularly effective against respiratory pathogens and has enhanced activity against gram-positive organisms compared to earlier fluoroquinolones.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: